ELVN Enliven Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Clinical-stage biopharma developing selective small molecule therapeutics targeting validated biology using precision medicine
• • New emphasis on ELVN-001, a selective ATP-competitive BCR-ABL TKI for CML addressing resistance, off-target toxicity, and dosing challenges
• • Strategic pivot to prioritize ELVN-001; exploring strategic alternatives for ELVN-002 to focus resources on lead program
• • ENABLE Phase 1 trial enrolled 90 patients; 47% cumulative MMR rate by 24 weeks with favorable safety in heavily pretreated CML patients
• • CEO Rick Fair joined Dec 2025, bringing 25+ years pharma leadership including commercial launches for $23B oncology portfolio

Risk Factors

• • FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
• • Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact
• • Supply chain vulnerability: changes in manufacturing process require FDA comparability analysis and approval, possibly delaying clinical trials
• • Competitive risk: dependency on ELVN-001 amid high biopharma attrition rates and competing therapies impacting commercial acceptance
• • Financial risk: accumulated deficit $347.2M, net loss $103.7M in 2025, need for substantial additional funding to sustain operations

Management Discussion & Analysis

• • No revenue generated in FY 2025 or 2024; no expected revenue in foreseeable future
• • Net loss $103.7M in 2025 vs $89.0M in 2024; operating expenses $119.7M vs $104.6M; operating margin negative and worsening
• • R&D increased to $85.9M in 2025 from $80.8M in 2024; ELVN-001 external costs up $7.8M, ELVN-002 external costs down $12.8M; G&A rose to $33.8M from $23.8M driven by $9.6M higher stock comp
• • Cash, cash equivalents and marketable securities $462.6M at December 31, 2025; raised $230M in June 2025 Public Offering, $90M in March 2024 Private Placement, $40M via Sales Agreement through 12/31/2025
• • Management expects operating losses and R&D expenses to increase; cash runway covers at least next 12 months; key risks include clinical trial progress, regulatory approval, need for further capital raises, and macroeconomic/geopolitical uncertainties

What are the latest ELVN SEC filings in 2026?

Enliven Therapeutics, Inc. (ELVN) has filed a 10-K annual report on March 3, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ELVN file its most recent 10-K annual report?

Enliven Therapeutics, Inc. (ELVN) filed its most recent 10-K annual report on March 3, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ELVN 10-Q quarterly reports?

Enliven Therapeutics, Inc. (ELVN)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every ELVN 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ELVN filed recently?

Enliven Therapeutics, Inc. (ELVN)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ELVN insider trading activity (Form 4)?

SignalX aggregates every ELVN Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ELVN file with the SEC?

Enliven Therapeutics, Inc. (ELVN) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ELVN filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Enliven Therapeutics, Inc. (ELVN).

What is ELVN's SEC CIK number?

Enliven Therapeutics, Inc. (ELVN)'s SEC CIK (Central Index Key) number is 1672619. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1672619 to look up all ELVN filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ELVN return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Enliven Therapeutics, Inc. (ELVN) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.